Clarus Therapeutics and McGill University Announce Licensing Agreement to Develop and Commercialize Technology to Treat Coenzyme-Q10 Deficiencies

Published: 16 September 2021

Agreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to...

Mitochondria drive cell survival in times of need

Published: 22 September 2017

Discovery points to possible target for cancer drugs...

Scientists discover gene behind rare disorders

Published: 9 October 2012

International study with researchers at The Neuro reveals links with other neurodegenerative diseases...

Unleashing the watchdog protein

Published: 9 May 2013

Research opens door to new drug therapies for Parkinson’s disease

Popular antioxidant likely ineffective, study finds

Published: 6 March 2015

The popular dietary supplement ubiquinone, also known as Coenzyme Q10, is widely believed to function as an antioxidant, protecting cells against damage from free radicals. But a new study by...

Researchers open new path of discovery in Parkinson’s disease

Published: 27 June 2016

A team of scientists led by Dr. Michel Desjardins from the University of Montreal and Dr. Heidi McBride from the Montreal Neurological Institute and Hospital (MNI) at McGill University have...

Back to top